Preliminary experience of allogeneic stem cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH conditioning: an effective regimen with low procedure-related toxicity.

Preliminary experience of allogeneic stem cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH conditioning: an effective regimen with low procedure-related toxicity.

Autologous transplantation has an established role in the treatment of lymphoproliferative disorders, but allogeneic transplantation remains controversial. In an attempt to reduce the high procedure-related mortality reported with allografting in lymphoma, we have used BEAM (BCNU, etoposide, cytarab...

Disgrifiad llawn

Manylion Llyfryddiaeth
Prif Awduron:	Cull, G, Haynes, A, Byrne, J, Carter, G, Miflin, G, Rebello, P, Hale, G, Waldmann, H, Russell, N
Fformat:	Journal article
Iaith:	English
Cyhoeddwyd:	2000

Eitemau Tebyg

Allogeneic stem cell transplantation for lymphoproliferative disease using BEAM-Campath conditioning: An effective regime with low procedure-related toxicity.
gan: Cull, G, et al.
Cyhoeddwyd: (1999)

Evaluation of non-myeloablative conditioning combining beam with in vivo pre-transplant Campath-IG for allogeneic transplantation in patients with lymphoma.
gan: Russell, N, et al.
Cyhoeddwyd: (1999)

T cell depletion with CAMPATH-1 in allogeneic bone marrow transplantation.
gan: Hale, G, et al.
Cyhoeddwyd: (1988)

Risks of developing Epstein-Barr virus-related lymphoproliferative disorders after T-cell-depleted marrow transplants. CAMPATH Users.
gan: Hale, G, et al.
Cyhoeddwyd: (1998)

CAMPATH: from concept to clinic.
gan: Waldmann, H, et al.
Cyhoeddwyd: (2005)

Alemtuzumab (Campath-1H) in allogeneic stem cell transplantation: where do we go from here?
gan: Chakrabarti, S, et al.
Cyhoeddwyd: (2004)

COMBINED USE OF CAMPATH-1G IN-VIVO AND IN THE BAG IN ALLOGENEIC BONE-MARROW TRANSPLANTATION
gan: Fibbe, W, et al.
Cyhoeddwyd: (1993)

Specificity of monoclonal antibody Campath-1.
gan: Hale, G, et al.
Cyhoeddwyd: (1988)

Availability of Campath-1 antibodies for bone marrow transplantation.
gan: Hale, G, et al.
Cyhoeddwyd: (1995)

CAMPATH-1 monoclonal antibodies in bone marrow transplantation.
gan: Hale, G, et al.
Cyhoeddwyd: (1994)

CAMPATH-1H in inflammatory arthritis.
gan: Watts, R, et al.
Cyhoeddwyd: (1993)

The CAMPATH-1 antigen (CDw52).
gan: Hale, G, et al.
Cyhoeddwyd: (1990)

Campath 1 H "in the bag" is an effective method of GvHD prevention in allogeneic stem cell transplantation.
gan: Potter, M, et al.
Cyhoeddwyd: (2000)

Recent results using CAMPATH-1 antibodies to control GVHD and graft rejection.
gan: Hale, G, et al.
Cyhoeddwyd: (1996)

Anti-globulin responses to rat and humanized CAMPATH-1 monoclonal antibody used to treat transplant rejection.
gan: Rebello, P, et al.
Cyhoeddwyd: (1999)

Leukaemic relapse after Campath 1-treated bone-marrow transplantation for leukaemia.
gan: Waldmann, H, et al.
Cyhoeddwyd: (1987)

ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR LEUKEMIA USING CAMPATH-1 MONOCLONAL-ANTIBODIES AND POSTTRANSPLANT ALLOIMMUNIZATION WITH DONOR LYMPHOCYTES
gan: Naparstek, E, et al.
Cyhoeddwyd: (1993)

Reversal of allograft rejection using the monoclonal antibody, Campath-1G.
gan: Friend, P, et al.
Cyhoeddwyd: (1991)

CAMPATH-1 MOAB IN THE TREATMENT OF REFRACTORY AUTOIMMUNE THROMBOCYTOPENIC PURPURA (ATP)
gan: Lim, S, et al.
Cyhoeddwyd: (1993)

Campath-1 Abs 'in the bag' for hematological malignancies: the Cape Town experience.
gan: Novitzky, N, et al.
Cyhoeddwyd: (2004)

Efficient complement-mediated lysis of cells containing the CAMPATH-1 (CDw52) antigen.
gan: Xia, M, et al.
Cyhoeddwyd: (1993)

Preliminary results of an non-myeloablative conditioning regimen for allogeneic stem cell transplantation.
gan: Mackinnon, S, et al.
Cyhoeddwyd: (1999)

Monoclonal antibody therapy of chronic intraocular inflammation using Campath-1H.
gan: Isaacs, J, et al.
Cyhoeddwyd: (1995)

CAMPATH-IH in multiple sclerosis.
gan: Moreau, T, et al.
Cyhoeddwyd: (1996)

Impact on T-cell depletion and CD34+ cell recovery using humanised CD52 monoclonal antibody (CAMPATH-1H) in BM and PSBC collections; comparison with CAMPATH-1M and CAMPATH-1G.
gan: Williams, R, et al.
Cyhoeddwyd: (2000)

EFFECTS OF MONOCLONAL-ANTIBODIES OF THE CAMPATH SERIES INVIVO - REQUIREMENTS FOR EFFECTIVE ANTIBODY THERAPY
gan: Dyer, M, et al.
Cyhoeddwyd: (1988)

CAMPATH-1 monoclonal antibody therapy in severe refractory autoimmune thrombocytopenic purpura.
gan: Lim, S, et al.
Cyhoeddwyd: (1993)

ISOTYPE VARIANTS OF CAMPATH-1 ANTIBODY - REQUIREMENTS FOR EFFECTIVE ANTIBODY ACTION INVIVO
gan: Dyer, M, et al.
Cyhoeddwyd: (1989)

The effect of the serotherapy regimen used and the marrow cell dose received on rejection, graft-versus-host disease and outcome following unrelated donor bone marrow transplantation for leukaemia.
gan: Byrne, J, et al.
Cyhoeddwyd: (2000)

TREATMENT OF RHEUMATOID-ARTHRITIS WITH HUMANIZED ANTILYMPHOCYTE ANTIBODY CAMPATH-1H
gan: Watts, R, et al.
Cyhoeddwyd: (1992)

Rat monoclonal antibodies for bone marrow transplantation--the CAMPATH series.
gan: Waldmann, H, et al.
Cyhoeddwyd: (1985)

CAMPATH-1 antibodies in stem-cell transplantation.
gan: Hale, G, et al.
Cyhoeddwyd: (2001)

Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?
gan: Hale, G, et al.
Cyhoeddwyd: (2002)

Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype.
gan: Dyer, M, et al.
Cyhoeddwyd: (1989)

REMISSION INDUCTION IN PATIENTS WITH LYMPHOID MALIGNANCIES USING UNCONJUGATED CAMPATH-1 MONOCLONAL-ANTIBODIES
gan: Dyer, M, et al.
Cyhoeddwyd: (1990)

CAMPATH-1 FOR PREVENTION OF GRAFT-VERSUS-HOST DISEASE AND GRAFT-REJECTION - SUMMARY OF RESULTS FROM A MULTI-CENTRE STUDY
gan: Hale, G, et al.
Cyhoeddwyd: (1988)

RAT MONOCLONAL-ANTIBODIES FOR BONE-MARROW TRANSPLANTATION (BMT) - THE CAMPATH SERIES
gan: Waldmann, H, et al.
Cyhoeddwyd: (1985)

Sustained remission of severe resistant autoimmune neutropenia with Campath-1H.
gan: Killick, S, et al.
Cyhoeddwyd: (1997)

Campath-1H therapy in refractory ocular inflammatory disease.
gan: Dick, A, et al.
Cyhoeddwyd: (2000)

Alemtuzumab (CAMPATH-1H) for the treatment of acute rejection in kidney transplant recipients: long-term follow-up.
gan: Clatworthy, MR, et al.
Cyhoeddwyd: (2009)